Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1996, for Corniche Group Incorporated (not Lisata Therapeutics, Inc., as indicated in the metadata). The Company has been inactive since February 1996, following the appointment of receivers to its UK operating subsidiaries (Chessbourne International Limited and The Stationery Company Limited) and the subsequent receivership of its UK holding company. These events resulted in the loss of all operations and operating assets, which are now classified as discontinued operations. The Company is currently seeking interim financing to settle liabilities and identify potential acquisition targets.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 1996 | 6 Months Ended Sep 30, 1996 | Balance Sheet (Sep 30, 1996) |
|---|---|---|---|
| Net Sales | $0 | $0 | N/A |
| Operating Loss | $(35,610) | $(67,860) | N/A |
| Net Loss (Continuing Ops) | $(53,822) | $(103,784) | N/A |
| Total Assets | N/A | N/A | $1,339 |
| Cash and Equivalents | N/A | N/A | $398 |
| Total Current Liabilities | N/A | N/A | $424,228 |
| Stockholders' Deficiency | N/A | N/A | $(422,889) |
| Net Cash Used in Operations | N/A | $332 (Net cash provided) | N/A |
Note: The filing reports a net cash increase of $332 for the six months ended September 30, 1996, driven by the collection of receivables and an increase in notes payable, offsetting the operating loss.
Material Changes vs. Prior Period
- Revenue: Net sales remain at $0, consistent with the prior period, as the Company has no active operations.
- Expenses: Selling, General, and Administrative (SG&A) expenses decreased significantly to $35,610 for the quarter (from $183,503 in the prior year quarter) and $67,860 for the six months (from $271,201). This reduction is attributed to lower insurance, legal, and professional fees following the cessation of UK operations.
- Discontinued Operations: The prior year periods included massive losses from discontinued operations ($(1,474,056) for the quarter and $(2,759,290) for the six months). The current period shows $0 from discontinued operations as the subsidiaries were removed from the balance sheet in late 1995.
- Liquidity: Cash increased from $66 to $398. However, the Company remains in a severe liquidity crisis with a stockholders' deficiency of $(422,889) and current liabilities of $424,228.
Outlook, Risks, and Contingencies
- Going Concern: The Company's ability to continue as a going concern is uncertain and depends entirely on obtaining outside financing to support operations pending a suitable acquisition. There is no assurance such financing will be obtained.
- Financing Activities: The Company conducted a private offering of securities (Rule 506) from July to December 1996. By September 30, 1996, 3 units were sold for $75,000 gross proceeds. The offering was terminated in December 1996 after selling 4 units total. A subsequent offering in early 1997 sold 17 units.
- Debt and Receivables:
- Notes Receivable: A $200,000 note from Chester Holdings, Ltd. was partially collected ($125,000 received by July 1996). The remaining $75,000 balance was provisioned for at March 31, 1996, with no further recovery anticipated.
- Notes Payable: The Company is in default on a $17,000 note (settled in March 1997 for $5,000). It also holds a $77,630 note payable on debt compromise to the Bank of Scotland, which was paid in full in January 1997.
- Legal Proceedings: The Company settled class action securities complaints in 1994 (paid $2.56M cash and issued $1M preferred stock). A derivative action was dismissed in May 1995. A lawsuit against former CEO Efriam Landa was settled in December 1996 via mutual releases.
- Tax Compliance: The Company is delinquent in filing Federal and State Income Tax returns for fiscal years 1994, 1995, and 1996.
Investor Verification Checklist
- Identity Verification: Confirm the registrant is Corniche Group Incorporated, not Lisata Therapeutics, Inc.
- Operational Status: Verify the Company has no active revenue-generating operations and is solely focused on financing and potential acquisitions.
- Liquidity Crisis: Assess the ability to meet current liabilities of $424,228 with only $398 in cash.
- Debt Settlements: Review the terms of the debt compromise with the Bank of Scotland and the settlement of the $17,000 note payable.
- Tax Delinquency: Investigate the status of delinquent tax filings and potential penalties.
- Subsequent Events: Note the January 1997 transfer of pledged securities and the full payment of the Bank of Scotland note, which occurred after the reporting period.